Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyphema: diagnosis and management.

J D Gottsch1

  • 1Wilmer Ophthalmologic Institute, Johns Hospital, Baltimore, Maryland 21205.

Retina (Philadelphia, Pa.)
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Antifibrinolytic agents show promise in preventing secondary hemorrhages from traumatic hyphema. Further research is needed to confirm efficacy across diverse patient populations, including children and those with sickle cell disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune defense at the ocular surface.

Eye (London, England)·2003
Same author

First do no harm: routine use of aminoglycosides in the operating room.

Insight (American Society of Ophthalmic Registered Nurses)·2002
Same author

Microarray analysis of gene expression in human donor corneas.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Spontaneous corneal perforation in a patient with unusual unilateral pellucid marginal degeneration.

Journal of cataract and refractive surgery·2001
Same author

EMAP cytokine expression in developing retinas of normal and retinal degeneration (rd) mutant mice.

Journal of neuroimmunology·2001
Same author

Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers.

Transactions of the American Ophthalmological Society·2001
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES: A NOVEL SURGICAL TECHNIQUE.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
Same journal

L-Suture Technique for Transscleral Intraocular Lens Fixation.

Retina (Philadelphia, Pa.)·2026
Same journal

Inherited Retinal Disease Management in the United States: A Survey of Clinician Practice Patterns.

Retina (Philadelphia, Pa.)·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Trauma Care

Background:

  • Traumatic hyphema management has a history of controversial treatments.
  • Previous interventions to prevent secondary hemorrhage have often been abandoned due to lack of evidence.

Purpose of the Study:

  • To review the current understanding of traumatic hyphema management.
  • To highlight the efficacy of antifibrinolytic agents in preventing secondary hemorrhages.
  • To identify unanswered questions regarding antifibrinolytic use in specific populations.

Main Methods:

  • Literature review of studies on traumatic hyphema management.
  • Analysis of prospective studies on antifibrinolytic agents.
  • Identification of research gaps concerning patient demographics and hemoglobinopathies.

Related Experiment Videos

Main Results:

  • Published studies indicate antifibrinolytic agents are effective in preventing secondary hemorrhages.
  • Efficacy in pediatric patients, different racial groups, and those with sickle cell disease remains under investigation.

Conclusions:

  • Successful traumatic hyphema treatment requires risk factor identification and appropriate medical or surgical management.
  • Antifibrinolytic agents represent a promising therapeutic avenue, but further research is warranted for comprehensive application.